| Unexpected radiation protection with 13-cis-retinoic acid plus interferon alpha-2a. | |
| | |
MedLine Citation:
|
PMID: 8306419 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A recent clinical protocol combining retinoic acid, interferon, and radiotherapy for advanced cervical cancer produced proctitis severe enough to necessitate dose reductions. In an attempt to model this biological response to multimodality therapy, we used a murine model to study the response of the colonic epithelium. Mice were treated with retinoic acid (100 micrograms/day) and interferon (3 x 10(4) units/day) for 5 days before undergoing whole-body irradiation. The functional response of the bowel was assessed by the ability to maintain body weight, and reproductive cell survival was quantified by the colon crypt assay. Both assays indicated a moderate protective effect of treatment with retinoic acid and interferon prior to irradiation. Protection factors in the range of 1.1-1.4 were observed. |
| | |
Authors:
|
K A Mason; P J Tofilon |
Related Documents
:
|
8884149 - Sebum excretion rate in subjects treated with oral all-trans-retinoic acid. 15964269 - Somite formation: where left meets right. 2515789 - Light and electron microscopic study of hamster cheek pouch treated with 9,10 dimethyl ... 1718279 - Retinoylation of cytokeratins in normal human epidermal keratinocytes. 17065529 - Retinal pigment epithelium rescues vascular endothelium from retinoic acid-induced apop... 17300159 - The fate of trans-caftaric acid administered into the rat stomach. 3995929 - Partial characterization of transferrins of catfish (silurus glanis l.) and pike (esox ... 20868659 - Hypotensive activity of an n-butanol extract and their purified compounds from leaves o... 18057699 - Xylarinic acids a and b, new antifungal polypropionates from the fruiting body of xylar... |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 33 ISSN: 0344-5704 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 1994 |
Date Detail:
|
Created Date: 1994-03-17 Completed Date: 1994-03-17 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 435-7 Citation Subset: IM |
Affiliation:
|
Department of Experimental Radiotherapy, University of Texas M.D. Anderson Cancer Center, Houston 77030. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cell Survival / drug effects, radiation effects Clone Cells Female Interferon Alfa-2a / pharmacology* Isotretinoin / pharmacology* Mice Mice, Inbred C3H Radiation Injuries, Experimental / prevention & control* Radiation-Protective Agents / pharmacology* Weight Loss / drug effects, radiation effects |
| Grant Support | |
ID/Acronym/Agency:
|
CA06294/CA/NCI NIH HHS; CA16672/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Radiation-Protective Agents; 4759-48-2/Isotretinoin; 76543-88-9/Interferon Alfa-2a |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as dete...
Next Document: A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carc...